Cargando…
Leishmania Immunity: Advancing Immunotherapy and Vaccine Development
Parasitic diseases still constitute a major global health problem affecting billions of people around the world. These diseases are capable of becoming chronic and result in high morbidity and mortality. Worldwide, millions of people die each year from parasitic diseases, with the bulk of those deat...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465679/ https://www.ncbi.nlm.nih.gov/pubmed/32784615 http://dx.doi.org/10.3390/microorganisms8081201 |
_version_ | 1783577642311614464 |
---|---|
author | Ikeogu, Nnamdi M. Akaluka, Gloria N. Edechi, Chidalu A. Salako, Enitan S. Onyilagha, Chukwunonso Barazandeh, Aida F. Uzonna, Jude E. |
author_facet | Ikeogu, Nnamdi M. Akaluka, Gloria N. Edechi, Chidalu A. Salako, Enitan S. Onyilagha, Chukwunonso Barazandeh, Aida F. Uzonna, Jude E. |
author_sort | Ikeogu, Nnamdi M. |
collection | PubMed |
description | Parasitic diseases still constitute a major global health problem affecting billions of people around the world. These diseases are capable of becoming chronic and result in high morbidity and mortality. Worldwide, millions of people die each year from parasitic diseases, with the bulk of those deaths resulting from parasitic protozoan infections. Leishmaniasis, which is a disease caused by over 20 species of the protozoan parasite belonging to the genus Leishmania, is an important neglected disease. According to the World Health Organization (WHO), an estimated 12 million people are currently infected in about 98 countries and about 2 million new cases occur yearly, resulting in about 50,000 deaths each year. Current treatment methods for leishmaniasis are not very effective and often have significant side effects. In this review, we discussed host immunity to leishmaniasis, various treatment options currently being utilized, and the progress of both immunotherapy and vaccine development strategies used so far in leishmaniasis. We concluded with insights into what the future holds toward the fight against this debilitating parasitic disease. |
format | Online Article Text |
id | pubmed-7465679 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74656792020-09-04 Leishmania Immunity: Advancing Immunotherapy and Vaccine Development Ikeogu, Nnamdi M. Akaluka, Gloria N. Edechi, Chidalu A. Salako, Enitan S. Onyilagha, Chukwunonso Barazandeh, Aida F. Uzonna, Jude E. Microorganisms Review Parasitic diseases still constitute a major global health problem affecting billions of people around the world. These diseases are capable of becoming chronic and result in high morbidity and mortality. Worldwide, millions of people die each year from parasitic diseases, with the bulk of those deaths resulting from parasitic protozoan infections. Leishmaniasis, which is a disease caused by over 20 species of the protozoan parasite belonging to the genus Leishmania, is an important neglected disease. According to the World Health Organization (WHO), an estimated 12 million people are currently infected in about 98 countries and about 2 million new cases occur yearly, resulting in about 50,000 deaths each year. Current treatment methods for leishmaniasis are not very effective and often have significant side effects. In this review, we discussed host immunity to leishmaniasis, various treatment options currently being utilized, and the progress of both immunotherapy and vaccine development strategies used so far in leishmaniasis. We concluded with insights into what the future holds toward the fight against this debilitating parasitic disease. MDPI 2020-08-07 /pmc/articles/PMC7465679/ /pubmed/32784615 http://dx.doi.org/10.3390/microorganisms8081201 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ikeogu, Nnamdi M. Akaluka, Gloria N. Edechi, Chidalu A. Salako, Enitan S. Onyilagha, Chukwunonso Barazandeh, Aida F. Uzonna, Jude E. Leishmania Immunity: Advancing Immunotherapy and Vaccine Development |
title | Leishmania Immunity: Advancing Immunotherapy and Vaccine Development |
title_full | Leishmania Immunity: Advancing Immunotherapy and Vaccine Development |
title_fullStr | Leishmania Immunity: Advancing Immunotherapy and Vaccine Development |
title_full_unstemmed | Leishmania Immunity: Advancing Immunotherapy and Vaccine Development |
title_short | Leishmania Immunity: Advancing Immunotherapy and Vaccine Development |
title_sort | leishmania immunity: advancing immunotherapy and vaccine development |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465679/ https://www.ncbi.nlm.nih.gov/pubmed/32784615 http://dx.doi.org/10.3390/microorganisms8081201 |
work_keys_str_mv | AT ikeogunnamdim leishmaniaimmunityadvancingimmunotherapyandvaccinedevelopment AT akalukaglorian leishmaniaimmunityadvancingimmunotherapyandvaccinedevelopment AT edechichidalua leishmaniaimmunityadvancingimmunotherapyandvaccinedevelopment AT salakoenitans leishmaniaimmunityadvancingimmunotherapyandvaccinedevelopment AT onyilaghachukwunonso leishmaniaimmunityadvancingimmunotherapyandvaccinedevelopment AT barazandehaidaf leishmaniaimmunityadvancingimmunotherapyandvaccinedevelopment AT uzonnajudee leishmaniaimmunityadvancingimmunotherapyandvaccinedevelopment |